Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Reaffirmed by Chardan Capital

Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “buy” rating reiterated by stock analysts at Chardan Capital in a note issued to investors on Friday, Benzinga reports. They currently have a $225.00 price objective on the biopharmaceutical company’s stock. Chardan Capital’s price target would indicate a potential upside of 47.71% from the company’s previous close.

Other research analysts have also issued reports about the company. StockNews.com upgraded Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, April 29th. JPMorgan Chase & Co. raised their price target on Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the company a “neutral” rating in a report on Thursday, February 1st. Morgan Stanley dropped their price objective on Alnylam Pharmaceuticals from $184.00 to $176.00 and set an “equal weight” rating for the company in a report on Tuesday, February 13th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $165.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. Finally, Wolfe Research initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 15th. They set a “peer perform” rating for the company. Seven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $215.88.

Alnylam Pharmaceuticals Stock Up 1.3 %

Shares of NASDAQ ALNY opened at $152.33 on Friday. Alnylam Pharmaceuticals has a 12-month low of $141.98 and a 12-month high of $218.88. The firm’s 50-day simple moving average is $149.65 and its 200 day simple moving average is $165.14. The company has a market cap of $19.19 billion, a price-to-earnings ratio of -56.84 and a beta of 0.41.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.23. The company had revenue of $494.33 million for the quarter, compared to analyst estimates of $428.01 million. During the same quarter in the previous year, the company posted ($1.40) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 54.8% on a year-over-year basis. On average, equities analysts expect that Alnylam Pharmaceuticals will post -4.46 earnings per share for the current year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several large investors have recently modified their holdings of ALNY. ANTIPODES PARTNERS Ltd grew its position in shares of Alnylam Pharmaceuticals by 69.1% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 189,141 shares of the biopharmaceutical company’s stock valued at $36,203,000 after purchasing an additional 77,307 shares during the period. Vanguard Group Inc. increased its position in shares of Alnylam Pharmaceuticals by 0.3% during the third quarter. Vanguard Group Inc. now owns 11,656,831 shares of the biopharmaceutical company’s stock worth $2,064,425,000 after acquiring an additional 30,608 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Alnylam Pharmaceuticals by 630.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 26,160 shares of the biopharmaceutical company’s stock worth $5,007,000 after acquiring an additional 22,580 shares during the period. Asset Management One Co. Ltd. lifted its position in Alnylam Pharmaceuticals by 41.3% in the 4th quarter. Asset Management One Co. Ltd. now owns 69,334 shares of the biopharmaceutical company’s stock valued at $13,569,000 after acquiring an additional 20,268 shares in the last quarter. Finally, Royal London Asset Management Ltd. boosted its stake in Alnylam Pharmaceuticals by 86.7% in the 3rd quarter. Royal London Asset Management Ltd. now owns 306,595 shares of the biopharmaceutical company’s stock worth $54,303,000 after purchasing an additional 142,357 shares during the period. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.